Abstract
Background:
In carcinogenesis, methylation of DNA promoter regions results in inactivation of tumor-suppressing genes. MG98 was designed to inhibit DNA methyltransferases enzyme 1 production.
Methods:
This multicenter study explored two schedules of MG98 with Interferon-α-2β to identify schedule and dose for patients with metastatic RCC.
Results:
Doses of IFN 9 MIU/MG98 125 mg/m(2) for a continuous schedule and IFN 9 MIU/MG98 200 mg/m(2) for an intermittent schedule were considered the MTDs. Treatment resulted in one PR and eight SD.
Conclusion:
MG98 combined with IFN was safe and resulted in clinical activity.
Publication types
-
Multicenter Study
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Aged
-
Carcinoma, Renal Cell / drug therapy*
-
Carcinoma, Renal Cell / mortality
-
DNA (Cytosine-5-)-Methyltransferase 1
-
DNA (Cytosine-5-)-Methyltransferases / antagonists & inhibitors*
-
Disease-Free Survival
-
Humans
-
Kidney Neoplasms / drug therapy*
-
Kidney Neoplasms / mortality
-
Middle Aged
-
Oligodeoxyribonucleotides / adverse effects
-
Oligodeoxyribonucleotides / therapeutic use*
-
Thionucleotides / adverse effects
-
Thionucleotides / therapeutic use*
Substances
-
MG 98 phosphorothioate antisense oligodeoxynucleotide
-
Oligodeoxyribonucleotides
-
Thionucleotides
-
DNA (Cytosine-5-)-Methyltransferase 1
-
DNA (Cytosine-5-)-Methyltransferases
-
DNMT1 protein, human